Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
Medtronic
Baxter
US Army
Covington
Deloitte
Harvard Business School
Boehringer Ingelheim

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206334

« Back to Dashboard

NDA 206334 describes ORBACTIV, which is a drug marketed by Melinta Therap and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the ORBACTIV profile page.

The generic ingredient in ORBACTIV is oritavancin diphosphate. Two suppliers are listed for this compound. Additional details are available on the oritavancin diphosphate profile page.
Summary for 206334
Tradename:ORBACTIV
Applicant:Melinta Therap
Ingredient:oritavancin diphosphate
Patents:3
Suppliers and Packaging for NDA: 206334
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334 NDA The Medicines Company 65293-015 N 65293-015-03
ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334 NDA Melinta Therapeutics, Inc. 70842-140 N 70842-140-03

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;IV (INFUSION)StrengthEQ 400MG BASE/VIAL
Approval Date:Aug 6, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 6, 2024
Regulatory Exclusivity Use:GENERATING ANTIBIOTIC INCENTIVES NOW
Regulatory Exclusivity Expiration:Aug 6, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:➤ Sign UpPatent Expiration:Aug 29, 2029Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE

Expired US Patents for NDA 206334

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Sign Up ➤ Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
UBS
Covington
Fish and Richardson
Cipla
Julphar
US Army
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.